Researchers at Dongguan Maternal and Child Health Care Hospital in China retrospectively analyzed 99 children born small for gestational age who had either failed to show catch-up growth, presented with multisystem anomalies, or both. Using trio-based whole-exome sequencing, in which the affected child and both parents are sequenced together, the team searched for the genetic roots of these children’s conditions. The results were striking: a confirmed molecular diagnosis was established in 59 of the 99 children, a diagnostic yield of 59.6 percent.

Trio-based whole-exome sequencing works by capturing and reading the protein-coding portions of the genome—the exome—in all three members of a family. Because the parents’ sequences are available for comparison, scientists can determine whether a suspicious variant was inherited from a carrier parent or arose spontaneously in the child. This segregation analysis is critical for interpreting variants correctly, since the same DNA change can be harmless in one context and disease-causing in another.

The study’s methodology went beyond simple sequence analysis. In addition to examining single-nucleotide and small insertion-deletion variants, the researchers mined the sequencing read-depth data to infer copy-number variants—large deletions or duplications of chunks of chromosomes that conventional exome pipelines often miss. Sequence variants were confirmed by Sanger sequencing, the older but highly accurate method of reading individual DNA fragments. Variants were then classified using the standards developed by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology for sequence variants, and the ACMG/ClinGen criteria for copy-number variants.

Only pathogenic or likely pathogenic findings whose inheritance pattern fit the family data were counted as molecular diagnoses. This conservative approach matters in clinical genetics, where over-interpretation of ambiguous variants can lead to false diagnoses. The team also identified four variants that remained classified as variants of uncertain significance—changes that could not be confidently labeled benign or disease-causing and therefore did not count toward the diagnostic yield.

Breaking down the 59 diagnoses, the researchers found considerable diversity in the underlying genetic architecture. Monogenic disorders—single-gene defects—accounted for the largest share, explaining 44 children, or 74.6 percent of the diagnosed cases. Copy-number variants explained 13 children, or 22.0 percent. Notably, two children received dual diagnoses, carrying both a disease-causing sequence variant and a pathogenic copy-number variant, a reminder that a single genetic explanation is not always sufficient.

The diagnostic yield differed meaningfully between the two clinical presentations. Among children with isolated failed catch-up growth—those born small who never caught up but had no other anomalies—trio-WES produced a diagnosis in 52.9 percent of cases, or 9 of 17 children. Among children with multisystem anomalies, the yield rose to 61.0 percent, or 50 of 82 children. The higher yield in the multisystem group aligns with genetic principles: when developmental disturbances affect multiple organ systems, a shared underlying genetic cause becomes more likely, and the genome search has more clinical features to anchor interpretations.

The clinical implications are considerable. A molecular diagnosis does more than attach a name to a condition. It can redirect management toward condition-specific surveillance and treatment, inform parents about recurrence risks for future pregnancies, and spare families a prolonged diagnostic odyssey of repetitive and often invasive testing. For children born small for gestational age, identifying a specific genetic syndrome may reveal risks—such as endocrine dysfunction, renal anomalies, or tumor predisposition—that would otherwise be missed. Genetic counselling grounded in an identified inheritance model allows clinicians to tell parents precisely whether the condition could recur in a subsequent child.

The authors are careful to draw boundaries around their conclusions. The 99 children in this study were not a random sample of all children born small for gestational age; they were a clinically selected, high-risk subgroup who had already raised concern because of persistent growth failure or anomalies affecting multiple systems. The researchers explicitly caution that the 59.6 percent diagnostic yield should not be generalized to the overall SGA population, most of whom are simply constitutionally small and healthy. Applying expensive genome-wide testing to every child born small, without clinical red flags, would produce far lower yields and risk incidental and ambiguous findings.

Still, the study adds to a growing body of evidence that trio-based genomic sequencing should be considered early rather than late in the evaluation of children with unexplained growth failure and congenital anomalies. As sequencing costs continue to fall and analytical tools improve—including methods that detect copy-number variants from exome data without separate chromosome microarray testing—the case for a single comprehensive genetic test at the start of the diagnostic journey grows stronger. For families facing the anxiety of a child who is not growing as expected, a faster path to answers may now be within reach.

Subject of Research: Use of trio-based whole-exome sequencing to diagnose genetic disorders in children born small for gestational age with failed catch-up growth or multisystem anomalies

Article Title: Clinical application of trio-based whole-exome sequencing in children born small for gestational age with failed catch-up growth or multisystem anomalies

Article References: Jiang, Z., Zhong, X., Lin, P., Yan, T., He, W., Guo, L., Xie, Y., Yuan, H., & Cheng, S. (2026). Clinical application of trio-based whole-exome sequencing in children born small for gestational age with failed catch-up growth or multisystem anomalies. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07633-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07633-5

Keywords: small for gestational age, trio whole-exome sequencing, failed catch-up growth, multisystem anomalies, molecular diagnosis, copy-number variants, genetic counselling, pediatrics, next-generation sequencing, rare variants, clinical genetics, Clinical

Autism spectrum disorder is a heterogeneous neurodevelopmental condition defined by differences in social communication and by restricted, repetitive patterns of behavior or interests. It affects roughly one in 100 children worldwide, yet its prevalence in African populations remains inconsistently documented. Decades of genomic research have established that autism is strongly genetic, with heritability estimates between 60 and 90 percent, driven by a combination of common polygenic risk and rare, high-impact variants. Despite this, African populations, which harbor the greatest genetic diversity on Earth, remain markedly underrepresented in sequencing studies and reference databases, leaving variant interpretation in these communities imprecise and diagnosis incomplete.

The Rwandan team recruited 34 children with a clinical diagnosis of autism, established through DSM-5-TR criteria and the Autism Diagnostic Interview-Revised, along with both biological parents for each child. After first-tier Fragile X syndrome screening identified three positive cases, the remaining 31 trios underwent whole-exome sequencing on an Illumina NovaSeq6000 platform. The sequencing achieved a median coverage depth of approximately 200-fold, with more than 97 percent of targeted regions covered at greater than 30-fold depth, ensuring high confidence in variant detection. Analyses were performed under ISO 15189-accredited protocols using clinically validated bioinformatic pipelines, with copy-number variants detected by an in-house tool and all variants classified according to ACMG and ClinGen standards.

The children in the cohort presented with a striking burden of additional neurodevelopmental features. Intellectual disability was present in nearly 97 percent of participants, delayed speech and language development in more than 80 percent, and global developmental delay in over half. Seizures affected roughly a quarter of the children, and dysmorphic features appeared in nearly a quarter. Most cases were classified as severe autism. This clinical complexity reflects the syndromic end of the autism spectrum, where autism occurs alongside intellectual disability, epilepsy, congenital anomalies, or other neurological signs, and it is precisely in such cases that exome sequencing tends to be most diagnostically productive.

The sequencing effort identified 11 rare genomic findings of potential clinical significance in nine patients. Four of these were classified as likely pathogenic, yielding a diagnostic rate of 12.9 percent, a figure that rises to 29 percent when variants of uncertain significance with strong phenotypic concordance are included. That range sits comfortably within the 10 to 30 percent diagnostic yields reported in large trio-based sequencing studies of autism in Europe and North America, suggesting that the genetic underpinnings of autism in Rwandan children are broadly comparable to those described elsewhere, even as the specific variants differ.

Among the likely pathogenic findings were two de novo single-nucleotide variants in well-established autism genes. One child carried a de novo missense variant in GABRB3, a gene encoding a GABA receptor subunit critical for inhibitory neurotransmission; the child’s early-onset seizures, intellectual disability, and language delay align with developmental and epileptic encephalopathy linked to this gene. Another child harbored a de novo splice-region variant in SYNGAP1, a key regulator of synaptic plasticity, in a presentation consistent with the global developmental delay and intellectual disability characteristic of SYNGAP1-related disorders. Both discoveries reinforce the central role of synaptic dysfunction in autism pathogenesis.

The study also uncovered two likely pathogenic copy-number variants. One patient carried a large de novo deletion on chromosome 1p35.3-p35.2 spanning dozens of genes, including dosage-sensitive contributors to neurodevelopment such as PUM1, SDC3, and MECR, associated with autism, hypotonia, seizures, and developmental delay. A second patient carried a deletion within the GNAS locus on chromosome 20q13.32, inherited from an unaffected parent, a finding that highlights the interpretive complexity of inherited variants and the roles of variable penetrance and expressivity in autism genetics.

Beyond the likely pathogenic results, the team identified seven variants of uncertain significance in genes including SHANK3, SYNJ1, KIF15, HUWE1, and EPG5. Several showed notable phenotypic overlap with known disorders: a de novo SHANK3 variant in a child with autism, developmental delay, and craniofacial anomalies echoes the spectrum of Phelan-McDermid syndrome, while compound heterozygous SYNJ1 variants in a child with epilepsy and intellectual disability fit with the gene’s established role in synaptic vesicle recycling. These variants cannot yet be deemed causative, but their concordance with published phenotypes makes them strong candidates for future functional studies and reclassification as evidence accumulates.

The researchers emphasize that the study’s single-site design and modest sample size limit statistical power, and that exome sequencing cannot capture non-coding regulatory variants or all structural variation. More fundamentally, the reliance on reference databases such as gnomAD and ClinVar, which incompletely represent African populations, likely inflated the proportion of variants of uncertain significance observed. Expanding African genomic reference datasets, the authors argue, is essential to improve variant classification, sharpen diagnostic accuracy, and ensure that the benefits of genomic medicine are distributed equitably rather than concentrated in well-studied populations.

Even with these caveats, the study marks a meaningful advance. It demonstrates that trio-based exome sequencing is feasible and clinically useful in Rwanda, capable of shortening the diagnostic odyssey for families, informing medical management, and clarifying recurrence risks for future pregnancies. The path forward, the authors conclude, lies in continued inclusion of ancestrally diverse populations, functional validation through RNA sequencing, splicing assays, and patient-derived neuronal models, and longitudinal phenotyping to translate genetic discovery into better care for children with autism worldwide.

Subject of Research: Trio-based whole-exome sequencing to identify rare genetic variants in Rwandan children with autism spectrum disorder

Article Title: Clinical Utility of Trio Exome Sequencing in Rwandan Children With Autism Spectrum Disorder

Article References: Hakizimana, O., Hitayezu, J., Uyisenga, J. P., Dukuze, N., Akimana, M. V., Mizero, L., Bampire, C., Mudenge, C., Butoto, X. K., Helou, L., Charloteaux, B., Caberg, J.-H., Dideberg, V., Palmeira, L., Alagbonsi, A. I., Bours, V., & Uwineza, A. (2026). Clinical Utility of Trio Exome Sequencing in Rwandan Children With Autism Spectrum Disorder. Molecular Genetics & Genomic Medicine, 14(9), Article e70294. https://doi.org/10.1002/mgg3.70294

Image Credits: AI Generated

DOI: 10.1002/mgg3.70294

Keywords: autism spectrum disorder, whole-exome sequencing, Rwanda, trio sequencing, genetic variants, copy-number variants, de novo mutations, GABRB3, SYNGAP1, SHANK3, genomic medicine, African genomics

Copy number variants, or CNVs, are deletions or duplications of stretches of DNA that can span anywhere from a few hundred bases to millions of bases and can remove, add, or disrupt entire genes. Unlike single-nucleotide variants, which change a single DNA letter, CNVs reshape the genome’s structural landscape, and when they occur in genes critical to brain development they can have outsized effects on neurodevelopmental and psychiatric outcomes. Several recurrent CNVs, such as deletions at the 22q11.2 locus, have been known for years to dramatically elevate schizophrenia risk, but nearly all of that knowledge was built on cohorts of predominantly European descent. Whether the same structural variants, or entirely different ones, contribute to schizophrenia in East Asian populations, which make up a substantial fraction of the world’s population and carry distinct patterns of genomic variation, remained an open and important question.

The new study addressed that question by assembling and analyzing genome-wide data from individuals of East Asian ancestry, comparing the burden of rare copy number variants in people diagnosed with schizophrenia against unaffected controls. The analytic strategy relied on high-quality genotyping arrays and sequencing-based calls that allow researchers to detect deletions and duplications across the genome, followed by careful filtering to remove likely artifacts and annotation of each variant against gene content, known disease loci, and measures of a gene’s intolerance to loss-of-function variation. Burden tests, which ask whether cases collectively carry more large, rare, gene-disrupting CNVs than controls, form the statistical backbone of this kind of work, and the study applied them with the sample sizes needed to detect effects that individual variants alone would be too rare to reveal.

The results confirmed that the fundamental burden signal holds across ancestries. People with schizophrenia in East Asian cohorts carried a significant excess of rare CNVs, particularly those that are large, that remove or duplicate many genes, and that overlap genes previously implicated in neurodevelopmental disorders. This is precisely the pattern observed in European studies, and its replication in an East Asian setting carries real weight: it suggests that the structural-variant contribution to schizophrenia is not an artifact of any one population’s genomic history or ascertainment, but a genuine and broadly shared feature of the disorder’s genetic architecture. For clinicians and researchers in East Asia, it also validates the use of CNV screening in psychiatric care and research contexts far beyond the populations in which those tools were originally developed.

Beyond confirming the overall burden, the analyses pinpointed specific rare copy number variants associated with schizophrenia in East Asian populations, contributing new population-specific resolution to a catalog of risk loci that has been heavily Eurocentric. Some of these signals overlap with CNV loci already known from European studies, reinforcing their status as reproducible schizophrenia risk factors, while the East Asian data add power and detail to their characterization. Because the frequencies of specific structural variants differ across populations, owing to drift, demographic history, and selection, mapping them in East Asian genomes is essential for building risk models and genetic counseling frameworks that actually fit the populations being served.

The most ambitious component of the work, however, was its meta-analysis. By combining East Asian results with those from large European ancestry studies, the investigators boosted statistical power well beyond what either cohort could achieve alone and searched for CNV loci associated with schizophrenia across ancestries. This trans-ancestry approach identified additional risk loci that no single population had the numbers to confirm on its own. The logic is straightforward: if a rare variant’s effect is genuine, pooling evidence across populations with different linkage disequilibrium patterns and different variant spectrums reduces confounding and sharpens the signal. Structural variants, which are often individually very rare and recently arisen, benefit especially from this strategy because their pathogenicity is less dependent on population-specific genetic background than that of common variants.

A striking unifying theme emerged from the annotation of these loci. The genes disrupted by the associated CNVs were significantly enriched for those that are intolerant to loss-of-function variants, meaning that in population sequencing databases, damaging mutations in these genes appear far less often than expected by chance. Genes under strong purifying selection in this way are typically those in which gene dosage matters: losing one copy, or gaining an extra one, perturbs biological systems enough to be selected against. In the brain, dosage-sensitive genes cluster in pathways governing synaptic function, neuronal development, and signaling. The finding that schizophrenia-associated CNVs converge on loss-of-function intolerant genes ties the disorder’s structural-variant risk to the same dosage-sensitive neurodevelopmental biology implicated by de novo mutations in autism, developmental delay, and congenital anomalies, reinforcing a picture of overlapping genetic mechanisms across neuropsychiatric conditions.

The implications run in several directions at once. Scientifically, the study helps close a long-standing gap in psychiatric genetics, demonstrating that rare structural variation is a universal contributor to schizophrenia risk and supplying East Asian-specific loci that will refine global catalogs of disease genes. Methodologically, it shows the value of building genomic resources in understudied populations and then integrating them through meta-analysis rather than extrapolating from European data. Clinically, dosage-sensitive CNV loci identified across ancestries could inform the emerging practice of returning secondary findings to psychiatric patients, since carriers of known pathogenic CNVs may benefit from surveillance for associated medical comorbidities. And for drug discovery, each new risk locus is a pointer toward biology, with dosage-sensitive genes offering mechanistic hypotheses about synaptic and developmental processes that go awry in psychosis.

The study also arrives amid a broader recalibration of how the field thinks about the genetics of schizophrenia. Genome-wide association studies have catalogued hundreds of common variant loci that collectively explain a large share of heritability but individually contribute tiny effects, while rare, high-impact variants such as large CNVs explain a smaller but more mechanistically tractable slice of risk. Rare structural variants, particularly those spanning multiple loss-of-function intolerant genes, are among the strongest known genetic risk factors for the disorder, and the demonstration that this risk architecture replicates in East Asian populations strengthens confidence that findings from these variants will translate broadly. The remaining challenges are considerable: sample sizes for rare variant discovery in non-European populations still lag far behind those in Europe, detection and comparison of CNVs across platforms and ancestries remains technically demanding, and translating locus discovery into biological understanding requires functional work well beyond association statistics.

Still, the trajectory is clear. Schizophrenia genetics has moved from single candidate genes to genome-wide surveys, from one continent to many, and from catalogs of associations to mechanistic principles such as dosage sensitivity and loss-of-function intolerance that bind risk loci into coherent biological stories. By showing that East Asian populations carry the same excess of rare, gene-disrupting copy number variants, and by using trans-ancestry pooling to surface additional risk loci enriched in genes that evolution refuses to let break, this work takes a significant step toward a genetic account of schizophrenia that genuinely fits the global population it affects. It is a reminder that the path to understanding a universal human illness must, by necessity, run through all of humanity’s genomes.

Subject of Research: Rare copy number variants associated with schizophrenia in East Asian populations

Article Title: Contribution of copy number variants to schizophrenia in East Asian populations

Article References: Chen, Y., Feng, Q., Lam, M., Yu, M., Sun, Y., Huai, C., Jana, B., Fu, J., Liao, C., Ye, R., Kim, S., Tubbs, J. D., Shanta, O., Thiruvahindrapuram, B., Jen, Y., Zhao, G., Wang, J., Stanley Global Asia Initiatives, Schwab, S. G., … Huang, H. (2026). Contribution of copy number variants to schizophrenia in East Asian populations. Nature Genetics. https://doi.org/10.1038/s41588-026-02732-6

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02732-6

Keywords: schizophrenia, copy number variants, East Asian populations, genomics, rare variants, meta-analysis, genetic risk loci, loss-of-function intolerance, Nature Genetics, psychiatric genetics, population genetics, neurodevelopmental genes